Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients

Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients

Targeting of αVβ3 and αVβ5 integrins by cilengitide may reduce growth of solid tumors including head and neck squamous cell carcinoma (HNSCC). Preclinical investigations suggest increased activity of cilengitide in combination with other treatment modalities. The only published trial in HNSCC (ADVAN...

Full description

Bibliographic Details
Main Authors: Susan Cedra, Susanne Wiegand, Marlen Kolb, Andreas Dietz, Gunnar Wichmann
Format: Article
Language:English
Published: MDPI AG 2017-09-01
Series:Cancers
Subjects:
head and neck cancer
head and neck squamous cell carcinoma (HNSCC)
predictive assay
chemoresponse ex vivo
cilengitide
integrin
αVβ3
targeted therapy
biomarker
interleukin 6
monocyte chemotactic protein-1
Online Access:https://www.mdpi.com/2072-6694/9/9/117

Similar Items

Similar Items